Veterinary Vaccines Market to Grow at a CAGR of 7.2% By 2032, Reaching New Heights
The global veterinary vaccines market is poised for significant growth, with the market size expected to reach USD 22.1 billion by 2032, up from USD 11.2 billion in 2022, reflecting a compound annual growth rate (CAGR) of 7.2% during the forecast period from 2022 to 2032. This robust expansion is driven by several key factors, including the increasing prevalence of zoonotic diseases, rising pet ownership, and advancements in vaccine technology.
One of the primary growth drivers is the heightened awareness and adoption of preventive healthcare measures for animals, which has led to an increased demand for effective immunization products. Technological advancements, such as the development of DNA and recombinant vaccines, have improved the efficacy and stability of vaccines, further fueling market growth. Moreover, government initiatives and investments in the pharmaceutical sector are boosting the production and availability of veterinary vaccines, particularly in regions like North America and Asia-Pacific.
However, the market faces challenges, including the high cost of vaccine development and regulatory hurdles. Additionally, the lack of awareness and adoption of animal immunization among smallholder farmers in developing regions poses a significant barrier to market penetration. Despite these challenges, ongoing research and development efforts and the introduction of new vaccine delivery technologies offer promising opportunities for market expansion.
Recent developments in the market include the launch of innovative vaccines and strategic acquisitions by major players. For example, Boehringer Ingelheim introduced Vaxxilive Cocci 3, a vaccine for poultry, while Zoetis expanded its product portfolio through the acquisition of Jurox, an Australian animal health company. These strategic moves are expected to strengthen the market presence of key companies and drive further growth in the veterinary vaccines market.
Key Takeaways
- The veterinary vaccines market is projected to reach USD 22.1 billion by 2032, with a compound annual growth rate (CAGR) of 7.2% from 2022.
- Advancements in veterinary vaccines, such as DNA and recombinant vaccines, improve stability and ease of administration.
- Recombinant vaccines are expected to drive market growth due to their safety and efficacy, with increased investments in quality production.
- The companion animals segment leads the market, supported by rising pet ownership and animal adoption rates globally.
- Parenteral administration, including intramuscular, subcutaneous, and intradermal options, is the predominant route for vaccine delivery.
- Porcine reproductive and respiratory syndrome holds the largest market share, given its high prevalence among livestock.
- Veterinary clinics are the primary distribution channel, with pharmacies and drug stores also experiencing growth.
- Market growth is driven by increasing awareness and the development of advanced vaccine products targeting zoonotic diseases.
- North America dominates the market due to high prevalence of zoonotic diseases and favorable compensation programs.
- Europe is the second-largest regional market, propelled by government guidelines, pet insurance adoption, and improved healthcare infrastructure.
Get Sample PDF Report: https://market.us/report/veterinary-vaccine-market/request-sample/
Veterinary vaccines Market Key Segments
By Product
- Attenuated Live Vaccines
- Inactivated
- Toxoid Vaccines
- Recombinant Vaccines
- Subunit Vaccines
- Conjugate Vaccines
- DNA Vaccines
By Animal
- Porcine Vaccine
- Poultry Vaccine
- Livestock Vaccine
- Bovine Vaccines
- Small Ruminant Vaccine
- Companion Animal Vaccine
- Canine Vaccine
- Feline Vaccine
- Aquaculture Vaccines
- Other Animal Vaccine
By Route of Administration
- Oral
- Parenteral
- Others
By Disease Indication
- Porcine Reproductive and Respiratory Syndrome
- Avian Influenza
- Rabies
- Coccidiosis
- Swine Pneumonia
- Brucellosis
- Canine Parvovirus
- Anaplasmosis
- Distemper Disease
- Foot and Mouth Disease
By Distribution Channel
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies
- Drug Stores
- Others
Key Regions
- North America (The US, Canada, Mexico)
- Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
- Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
- APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
- Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
- Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)
Buy Directly: https://market.us/purchase-report/?report_id=20089
Key Players Analysis
Elanco Animal Health is a key player in the veterinary vaccines market, focusing on innovative solutions for animal health. Recently, Elanco sold its aqua business to MSD Animal Health for $1.3 billion. This divestiture allows Elanco to concentrate more on its core animal health sectors, particularly in vaccines and treatments for farm animals and pets. Elanco continues to leverage its nearly 70 years of expertise to develop products that enhance animal health and well-being, benefiting farmers, veterinarians, and pet owners worldwide.
Boehringer Ingelheim is a leading company in veterinary vaccines, known for its strong R&D capabilities and extensive product portfolio. The company offers vaccines for a wide range of animals, including poultry, swine, cattle, and pets. Their innovative vaccines help prevent diseases, improving animal health and productivity. Boehringer Ingelheim’s commitment to research and development ensures a continuous pipeline of new and effective vaccines, addressing emerging health challenges in the veterinary sector.
HIPRA is a specialized veterinary pharmaceutical company, emphasizing biological products such as vaccines. HIPRA develops and manufactures vaccines for various species, including poultry, swine, cattle, and pets. The company’s integrated approach, from R&D to production, ensures high-quality and effective vaccines. HIPRA’s innovative technologies and commitment to animal health make it a significant player in the global veterinary vaccines market.
Merck Animal Health, known as MSD Animal Health outside the U.S., is a global leader in the veterinary vaccines sector. The company recently acquired Elanco’s aqua business, enhancing its portfolio with advanced vaccines and treatments for aquaculture. Merck’s extensive range of vaccines covers multiple species, including livestock and pets, aiming to prevent diseases and improve animal health. Their continuous investment in research and development drives innovation in veterinary vaccines.
Virbac is a prominent company in the veterinary vaccine industry, offering a comprehensive range of products for companion animals, livestock, and aquaculture. Virbac’s vaccines are designed to prevent a variety of diseases, enhancing animal health and productivity. The company’s focus on innovation and quality ensures that its vaccines meet the highest standards, addressing the needs of veterinarians and animal owners globally.
Veterinary vaccines Market Key Players:
- Elanco Animal Health Incorporated
- Boehringer Ingelheim International GmbH
- HIPRA
- Merck& Co, Inc.
- Virbac
- Vetoqional S. A
- ADM Animal Nutrition
- Evonik Industries AG
- Zoetis Inc.
- MSD Animal Health
- Hester Biosciences Limited
- Ceva Logistics
- Neogen Corporation Limited
- Biogenesis Bago S A
- Kindered Biosciences, Inc.
- Bayer AG
- Indian Immunologicals Ltd
- Eli Lilly and Company
- Phibro Animal Health Corporation
- Other Key Players
Veterinary vaccines Market Report Scope >> Market Value (2022): USD 11.2 Billion || Forecast Revenue (2032): USD 22.1Billion || CAGR (2023-2032): 7.2% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.
Inquire More about report: https://market.us/report/veterinary-vaccine-market/#inquiry
About Market.US
Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.
Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: inquiry@market.us
Blog: https://medicalmarketreport.com/
View More Trending Reports
Healthcare BPO Market Estimated To Reach USD 908 Billion By 2032, With Round About 9.9% CAGR
Dental 3D Printing Market Economic Projections Soar To USD 19.6 Billion By 2032, With 23.03% CAGR
Peptide Therapeutics Market Predicted USD 90 Billion By 2033, An Approximate 8.9% CAGR Growth
Editor Details
-
Company:
- Wired Release
- Website:
